ArticleUpdates in surgery2026
Early unresectable relapse after hepatic resection for colorectal liver metastases: a focus on time to surgical failure.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CT-based radiomics improves survival prediction in colorectal liver metastases: beyond clinical scores.Updates in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatic resection is the only potential cure for colorectal liver metastases (CRLMs), but early recurrence is common. Re-resections provide long-term survival benefits. Time to Surgical Failure (TSF), defined as the time from liver resection to unresectable recurrence, may be a more reliable surrogate for overall survival (OS) than disease-free survival (DFS). Despite curative surgeries, unresectable hepatic relapse within 12 months is frequent, raising concerns about the surgical benefits. Study aims were to evaluate the association between TSF and OS in patients with CRLMs undergoing curative resections, and to identify factors associated with futile surgery (unresectable recurrence or death within 12 months). A monocentric, retrospective study was conducted using data from 183 patients who underwent curative hepatic resection for CRLMs at San Raffaele Hospital, between 2019 and 2024. TSF, DFS, and OS were evaluated using Kaplan–Meier curves and correlation analyses. Univariable and multivariable logistic regression analyses were used to assess factors associated with futile surgery. After a median follow-up of 18 months, 30% patients died, 51% relapsed, and 41% developed unresectable hepatic recurrences. TSF better correlated with OS than DFS in both alive (rs = 0.61, p < 0.0001; rs = 0.37, p = 0.003) and dead (rs = 0.45, p = 0.008; rs = 0.29, p = 0.12) patients. Age > 65 years, KRAS mutation, T4 primary tumor stage, and absence of adjuvant chemotherapy associated with higher rates of futile surgery, though none were independent predictors. TSF appears to be a more reliable surrogate for OS than DFS in patients with resected CRLMs. Larger studies are needed to validate our findings.
Indexed as
Identifiers
41381989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.